Skip to Main Content

Message delivered — with a punch to the face.

Earlier this week, Richard Pazdur, the Food and Drug Administration’s top cancer drug regulator, told STAT that he intended to use an upcoming advisory meeting to make clear to U.S. drug companies that data from cancer clinical trials conducted entirely in China would not be sufficient for approval here.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment